top of page
All Posts
Delphian Therapeutics' Cannabinoid Migraine Research Named Editor's Choice in the Journal of the International Headache Society
Research on combined CBD and THC for migraine, by E. Zorrilla et al., was named Cephalalgia Editor's Choice for February 2025 by the International Headache Society.
Delphian Therapeutics Awarded $2.9M Phase 2 SBIR Grant from NIH to Advance Cannabinoid Migraine Drug to First-in-Human Clinical Trials
Delphian Therapeutics received a $2.9M Phase 2 SBIR grant from the U.S. National Institutes of Health to advance its patented CBD:THC migraine formulation through IND clearance and into Phase 1 clinical trials.
Delphian Therapeutics Closes $2.7M Seed Round to Advance S1-221 Cannabinoid Migraine Therapeutic into Phase 1 Clinical Trials
Delphian Therapeutics closed a $2.7M seed round to advance S1-221, its patented CBD:THC combination for migraine, into Phase 1 clinical trials. The program is funded in part by NIH and the Migraine Research Foundation.
bottom of page